Large Molecule Research: Higher Targeting Efficiencies Still Leave Room for Automation

The rise of biopharmaceuticals has evolved research paradigms and continues to displace use of traditional small molecule therapies in the market. Biologics are forecast to account for more than half of the Top 100 selling drugs by 2022, up from roughly one-third in 2012. Driving these therapies to market has required significant investment in upfront […]

Automation is Closing the DNA Read-Write Gap

SYNTHETIC BIOLOGY DEPENDS ON AUTOMATION Genomics has been the focal point of life sciences research over the past decade, enabling a better understanding of disease beyond its physical manifestation and into its underlying drivers. This has opened significant opportunities across the therapeutic spectrum in both disease diagnosis and treatment. These advances would not have been […]